William H. Bradley, MD
William H. Bradley, MD

William H. Bradley, MD

Assistant Professor

Bradley, William H., MD

July 15, 2013  |  Doctors

Introduction

Dr. William Bradley joined the Department of Obstetrics and Gynecology as an Assistant Professor in the Division of Gynecology Oncology at the Medical College of Wisconsin in July, 2008. He received his Doctor of Medicine from the University of Minnesota in 2000, and subsequently went on to complete his residency in Obstetrics and Gynecology at the University of Minnesota in Minneapolis. After his four year residency, he continued his training in the subspecialty of Gynecology Oncology. Dr. Bradley completed a three year fellowship in Gynecology Oncology at The Mount Sinai School of Medicine in New York City. Dr. Bradley joined the Medical College of Wisconsin after completing his fellowship.

Dr. Bradley’s clinical practice includes the care of women with gynecologic malignancies including uterine, cervical, ovarian primary peritoneal, fallopian tube, vulvar and vaginal malignancies and gestational trophoblastic disease. He performs the surgery, the post-operative therapy if indicated, and the follow up surveillance of women in his practice. In addition, he is also interested in the treatment of women who have been diagnosed with pelvic masses, pre-cancerous lesions of the cervix, vulva, vagina or uterus, as well as cancer screening and prevention. He is trained and has expertise in the administration of chemotherapy for gynecologic malignancies, including intraperitoneal chemotherapy for ovarian malignancy. He has extensive expertise in minimally invasive surgery including general laparoscopy and robotic assisted laparoscopy.

Dr. Bradley’s academic interests include research into genetic causes of chemotherapy resistance in ovarian cancer, and he has recently been awarded a grant from the Women’s Health Research Program to further his work. Furthermore, he has been accepted as a Clinical & Translational Science Institute (CTSI) Clinical/Translational Research Scholar for the upcoming biennium.

Dr. Bradley’s publications focus on topics related to gynecologic oncology.

Dr. Bradley is a member of The American College of Obstetricians and Gynecologists (ACOG), The Society of Gynecologic Oncologists (SGO), The Milwaukee Gynecologic Society (MGS), and The American Society of Clinical Oncology (ASCO). He is board certified in gynecologic oncology and obstetrics and gynecology. He is active in the Milwaukee community and has given Medical Education Lectures at University of Wisconsin – Washington County as well as discussions at Small Stones. He has worked with The Wisconsin Ovarian Cancer Alliance (WOCA) and was the keynote speaker at the annual brunch in 2010.

Areas of Expertise

William H. Bradley, MD

William H. Bradley, MD

  • Gestational Trophoblastic Disease
  • Minimally Invasive Surgery
  • Pelvic Masses
  • Vulvar and Vaginal Cancers
  • Cancer Screening and Prevention
  • Ovarian Cancer
  • Cervical and Endometrial Cancer
  • Chemotherapy for Treatment of Gynecologic Cancers

Board Certification(s)

  • Obstetrics and Gynecology
  • Gynecologic Oncology

Patient Ages Seen

  • Infant (0-12 months)
  • Child (1-12 yrs)
  • Adolescent (13-18 yrs)
  • Adult (18 + )
  • Senior (60 +)

Languages Spoken

  • English

Education / Training

  • Doctor of Medicine – University of Minnesota Medical School – Minneapolis (2000)
  • Fellowship in Gynecology Oncology – Mount Sinai Medical Center – New York, NY (2005-2008)
  • Residency in Obstetrics & Gynecology – University of Minnesota Hospital and Clinic – Minneapolis (2000-2004)

MCW Start Date

  • 07/01/2008

Publications

Research

Principal Investigator
Study Title
Bradley, William H., MDGOG 277: A Phase III Randomized Trial of Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Bradley, William H., MDGOG 9927: A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888) and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Bradley, William H., MDGOG 9928: A Phase I Study of Intraperitoneal Egen-001 Administered in Combination with Pegylated Liposomal-Doxorubicin in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Bradley, William H., MDGOG 262: Suboptimally Debulked St. III or IV Primary Ovarian: A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC# 704865, IND# 7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer.
Bradley, William H., MDGOG 263: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Bradley, William H., MDGOG 0261: A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Bradley, William H., MDGOG 258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Bradley, William H., MDGOG 252: A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agents(s): Bevacizumab (NSC #704865, IND# 7921)
Bradley, William H., MDGOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube or Peritoneal Cancer Progression-Free Survival?
Bradley, William H., MDGOG 249: A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma
Bradley, William H., MDAmgen 386 Study 20090508: A Phase 3, Randomized, Double-blind Trial of Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Following a Prior Platinum-Containing Regimen
Bradley, William H., MDGOG 273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bradley, William H., MDGOG 268: A Phase II Evaluation of Temsirolimus in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary.
Bradley, William H., MDGOG 267: Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Bradley, William H., MDGOG 255: A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer who are in Second or Third Complete Remision
Bradley, William H., MDGOG 240: A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC# 704865, IND# 7921) versus the Non-Platinum Doublet, Topotecan plus Paclitaxel, with and without NCI-Supplied Bevacizumab in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
Bradley, William H., MDGOG 235: A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy
Bradley, William H., MDGOG 182: A Phase III Randomized Trial of Paclitaxel and Carboplatin versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma
Bradley, William H., MDGOG 184: A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Cancer
Bradley, William H., MDGOG 136 Tissue Bank: Acquisition of Human Gynecologic Specimens to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
Bradley, William H., MDGOG LAP 2: A phase III clinical trail of laparoscopic pelvic and para-aortic node sampling with vaginal hysterectomy and BSO versus open laparotomy with pelvic and para-aortic node sampling and abdominal hysterectomy and BSO in endometrial adenocarcinoma, clinical stage I, IIA, Grade I, II, III
Bradley, William H., MDGOG 86P: A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC#704865, IND#7921), Paclitaxel/Carboplatin/Temsirolimus (NSC#683864, IND #61010) and Ixabepilone (NSC#710428, IND# 59699) Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Bradley, William H., MDGOG 207: A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)
Bradley, William H., MDGOG 209: A Randomized Phase III Trial of Doxorubicin/ Cisplatin/ Paclitaxel/G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
Bradley, William H., MDGOG 219: A Phase III, Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine (IND# 46525) and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis
Bradley, William H., MDGOG 227E: A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
Bradley, William H., MDGOG 218: A Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab (NSC #704865, IND# 7921) Followed by Placebo versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian or Primary Peritoneal or Fallopian Tube Cancer
Bradley, William H., MDGOG 213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704965, IND# 7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Bradley, William H., MDGOG 212: Maintenance Chemo Vs No Treatment in Advanced Ovarian: a Randomized Phase III Trial of Maintance Chemotherapy Comparing 12. Monthly Cycles of single agent Paclitaxel or CT-2103 (IND# 70177) Versus No Treatment Until documented Relapse In women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer who Achieve a Complete Response to Primary Platinum/Taxane Chemotherapy
Bradley, William H., MDGOG 274: A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL
Bradley, William H., MDGOG 241: A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Bradley, William H., MDGOG 244: The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients
Bradley, William H., MDGOG-0214: Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Bradley, William H., MDGOG 272: Pilot Study of Standard Therapy for Prevention of Nausea Associated with First Line Post-operative Intraperitoneal Chemotherapy
Bradley, William H., MDGOG 3001: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers (Amgen Protocol #2010129)
Bradley, William H., MDGOG 3003: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 (IND#78,416) in Combination with Pegylated Liposomal Doxorubicin (PLD) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Bradley, William H., MDToward a Biomarker Driven Treatment for Ovarian Carcinoma

In the News

William Bradley, MD and Michael Lund, MD Recognized on the Top Physicians List from the Froedtert & MCW Patient Satisfaction Surveys

William Bradley, MD and Michael Lund, MD Recognized on the Top Physicians List from the Froedtert & MCW Patient Satisfaction Surveys

02/04/2014  |  Awards & Recognition

Dr. William H. Bradley and Dr. Michael R. LundWilliam Bradley, MD, Gynecologic Oncologist and Michael Lund, MD, Obstetrician and Gynecologist, recognized as… Read More ›

Best Doctors 2013-2014

Best Doctors 2013-2014

02/03/2014  |  Awards & Recognition

458 Medical College Doctors Recognized as Best Doctors in America

A total of 446 Medical College of Wisconsin (MCW) faculty physicians, representing 63 specialties, are listed… Read More ›

Froedtert & The Medical College of Wisconsin elevated to full member of Gynecologic Oncology Group

Froedtert & The Medical College of Wisconsin elevated to full member of Gynecologic Oncology Group

08/12/2013  |  Department News

Froedtert & The Medical College of Wisconsin have been elevated to full membership in the Gynecologic Oncology Group (GOG), a National Cancer Institute (NCI)-funded cooperative… Read More ›

2013 News from the Residency Program Campuses

2013 News from the Residency Program Campuses

06/18/2013  |  Resident & Alumni News

News from the Medical College of Wisconsin and Froedtert Hospital
Once again, we bring a successful year to a close in the MCWAH Obstetrics and Gynecology… Read More ›

Top OBGYN Physicians from the Patient Satisfaction Surveys

Top OBGYN Physicians from the Patient Satisfaction Surveys

04/24/2013  |  Department News

We would like to recognize those physicians who were highly ranked on the patient satisfaction surveys at Froedtert & The Medical College of Wisconsin. The… Read More ›

Best Doctors 2012-2013

Best Doctors 2012-2013

02/11/2013  |  Awards & Recognition

458 Medical College Doctors Recognized as Best Doctors in America

A total of 458 Medical College of Wisconsin (MCW) faculty physicians, representing 63 specialties, are listed… Read More ›

William Bradley, MD

WHRP: Grants Awarded to William Bradley, MD and Jian Huang, MD

06/01/2011  |  Department News

William Bradley, MD (pictured, right)Following a competitive peer-review process, two Medical College of Wisconsin scientists have received the first grants distributed… Read More ›

Individualized Treatment for Ovarian Cancer

Individualized Treatment for Ovarian Cancer

05/01/2011  |  Department News

As seen in: Froedtert Today, May, 2011Download the Full PDF

About 500 women are diagnosed with ovarian cancer annually in Wisconsin. Even… Read More ›

Dr. Bradley and his nurse were extremely kind and considerate. I was well taken care of.